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AbstrAct
Monitoring of chronic conditions accounts for a significant 
proportion of blood testing in UK primary care; not all 
of this is based on evidence or guidelines. National 
benchmarking shows significant variation in testing rates 
for common blood tests. This project set out to standardise 
the blood tests used for monitoring of chronic conditions 
in primary care across North Devon, and to measure 
and reduce the harms of unwarranted testing. Chronic 
disease test groups were developed in line with current 
guidelines and implemented using one-click electronic 
test ordering systems. The main difference from previous 
general practitioner practice algorithms was removing 
the requirement for full blood count and liver function test 
monitoring for many conditions. Baseline harms of testing 
were measured and included significant costs, workload 
and patient anxiety. By defining the scale of the problem, 
we were able to leverage change across several cycles 
of quality improvement, using a pathology optimisation 
forum for peer-led improvement, and developing a 
framework focusing on what matters to patients. Overall 
primary care testing rates in North Devon fell by 14% for 
full blood count testing and 22% for liver function tests, 
but without a reduction in the number of tests showing 
possible significant pathology. We estimate that this has 
reduced testing costs by £200 000 across a population 
of around 180 000 people and has reduced downstream 
referral costs by a similar amount. Introduction of simple 
chronic disease test groups into primary care electronic 
ordering systems, when used alongside engagement with 
clinicians, leads to both quality improvement and reduction 
in system costs.
Problem
The laboratory at North Devon District Hospital 
undertakes about 5.5 million tests per year for 
a population of approximately 180 000. A large 
proportion of this activity, for example, over 
50% of biochemical tests,1 is for the ongoing 
monitoring of chronic diseases in primary care, 
rather than for population health screening 
or diagnostic purposes. While some of this is 
supported by evidence-based guidelines, this 
is not universally the case, and a significant 
number of these tests may be unnecessary.2
A review of the content of chronic disease 
monitoring recommendations for the 20 
general practices in North Devon found that 
no two practices recommended the same set 
of tests. For example, the National Institute of 
Health and Care Excellence (NICE) guidance 
on lipid modification for the prevention of 
cardiovascular disease states that liver transami-
nase enzymes (usually alanine aminotransferase 
[ALT]) should be measured before starting 
a statin for lipid reduction, then at 3 and 12 
months after starting. Unless clinically indicated 
there is no need to continue ALT monitoring.3 
Despite this, 19 out of 20 General Practitioner 
(GP) practices in our locality included moni-
toring of ALT on an annual basis for patients 
on statins. Similarly, all but one practice 
included full blood counts (FBCs) in their 
chronic disease monitoring protocols, which 
are not part of NICE recommendations. Testing 
without a clear clinical rationale moves into the 
realm of de facto screening for occult disease. 
Such practice requires evaluation in context to 
ensure that benefits outweigh harms.4 In the 
absence of such evidence, we felt that the large 
amount of potentially unwarranted testing in 
chronic disease monitoring could be leading to 
patient harm.
In 2012, there were 81 465 primary care 
requests to the North Devon laboratory that 
generated at least one result that was outside 
a reference limit in FBC or liver function test 
(LFT). Approximately 25% of these came 
from requests that could easily be identified 
as part of chronic disease monitoring. As a 
preliminary exercise, we examined the conse-
quences on primary care workload of an ALT 
result outside reference ranges arising from 
chronic disease monitoring. We reviewed the 
case notes of 45 patients with chronic disease 
from two practices in whom the ALT was 
above the reference range:
 ► Thirty-four patients had the ‘abnormal’ 
result filed with no further action.
 ► Seven patients had the test repeated, 
which was within the reference range.
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 ► Four patients were seen again in a GP appointment to 
discuss the results.
 ► One patient received an ultrasound of the liver, identi-
fied as fatty liver (adding nothing to the management 
of a patient who could be seen to be obese).
 ► One previously well patient saw the GP 14 times in 
1 year, with multiple repeat tests. One patient had 
several GP appointments and referral for further 
investigation. Neither of these patients had significant 
pathology that altered management.
We looked for secondary care referrals in the year prior to 
implementation of test groups from a single pilot practice 
(list size 11 000 patients) that were generated as a result of 
an FBC that had been requested as part of chronic disease 
monitoring. We identified seven patients who fitted these 
criteria. These generated one haematology appointment, 
four gastroenterology appointments, one MRI head scan, 
one CT of the colon, four gastroscopies and four colonos-
copies. Two patients did not attend their appointments. 
No significant pathology was found in any patient. Two 
patients had benign polyps.
The estimated cost of these investigations is about 
£10 000. Extrapolating to our locality, the cost would be 
£200 000.
We interviewed a patient who described the effect on 
her life of detection of an incidental mild anaemia, and as 
a result produced a video in which she describes her expe-
riences.5 Other cases showed how a mildly elevated ALT 
can turn a citizen who is an infrequent user of medical 
services into a patient with high levels of dependence 
with multiple follow-up appointments. At one extreme, 
a patient had 14 follow-up appointments within a year, 
despite having no symptoms that would have suggested 
the need to check liver function in the first place. 
Another patient eventually stopped attending secondary 
care referrals as they were becoming so anxious about the 
investigations that had been put in train from a result just 
above the ALT reference range.
background
Approximately 80% of patient interactions with the 
National Health Service (NHS) involve pathology 
services, equating to about 200 million requests per year.6 
The NHS Atlas of Variation has demonstrated significant 
geographical variability in primary care pathology testing 
rates in the UK,7 which cannot be accounted for by differ-
ences in sociodemographic or other descriptive indica-
tors of GP practices.8 There is a large body of literature 
which has evaluated strategies to improve the ‘appropri-
ateness’ of blood tests, which has mostly been defined in 
terms of reduced testing rates or improved adherence to 
guidelines. These have included a variety of educational 
interventions,9 10 feedback,11–13 peer management,14 use 
of computer prompts,15 decision support tools16 and 
information about the costs of testing.17 These factors 
have been systematically reviewed.18–20
The potential for diagnostic tests to cause harm is 
increasingly recognised, and has led to the ‘Choosing 
Wisely’ initiative.21 A significant proportion of primary 
care testing arises from chronic disease monitoring, 
which is partially due to the requirements of achieving 
payment via the quality and outcomes framework (QOF) 
of the General Medical Services contract, which was intro-
duced in 2004.22 Most chronic diseases listed in QOF 
require some element of blood monitoring, usually on an 
annual basis. There is, however, little or no requirement 
to ensure that this monitoring is confined to tests that are 
necessary and sufficient to provide care.
Similarly, laboratory accreditation processes tend 
to focus on internal quality issues (eg, traceability of 
reagents) that do not reflect the impact, either positive 
or negative, of testing on patients. This suggested that 
our current definitions of success (eg, laboratory accred-
itation and compliance with QOF) might not necessarily 
reflect what matters to patients.
design
This programme had a number of aims:
 ► Describe the harms associated with the current 
approach to testing.
 ► To standardise the blood tests used for chronic disease 
management across North Devon starting from the 
position of defining what would constitute ‘necessary 
and sufficient’ testing for a particular patient.
 ► Derive an improvement framework based on engage-
ment and that promotes a shift from an ‘inside out’ 
view (seeing success from the perspective of the labo-
ratory) to an ‘outside in’ view (seeing success from the 
perspective of the patient).
To begin to explore what matters to patients undergoing 
diagnostic tests, we interviewed a small number of patients 
attending routine phlebotomy clinics. We found that, in 
general, although patients trusted healthcare professionals 
to keep them safe and well, they were not aware of what 
tests were being done. In addition, we found that patients 
wanted testing to tell them if they were ‘normal’, and if not, 
what needed to happen to return them to ‘normal’.
These findings are in line with larger studies23 and from 
these we derived a universal purpose statement that we 
felt reflected the purpose of laboratory medicine:
To help citizens, and their carers, make informed 
decisions about their care.
We call this an ‘outside-in’ view of how we might judge 
the success of laboratory medicine, in contrast to the 
‘inside-out’ view which would define success according to 
criteria such as cost and the meeting of internally derived 
standards (eg, turn around times).
Our initial work showed us that the current environ-
ment was not meeting this purpose. We met patients who 
had received results for tests they did not know were being 
done, and conversely met patients who had gained false 
reassurance from tests that had not been done. We saw 
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numerous examples of tests that were not necessary to 
answer the clinical question being asked, often leading to 
significant harm from ‘treating the result’. Conversely, we 
saw evidence of delayed and suboptimal decision-making 
due to a failure to carry out appropriate tests. Results 
generated by the laboratory were often presented in ways 
that obscured meaning and were prone to being misun-
derstood. In addition, results tended to reflect what 
is normal for a population. They rarely told us what is 
abnormal for the individual.
In order to address these issues and help ascertain 
whether service is optimally focused on the needs of the 
individual patients, we designed the ‘Clean Framework’. 
This includes three main points of focus, framed from 
the perspective of the patient, that each incorporated 
elements that we felt would have to be true, regardless of 
the specific clinical context.
Clean in
 ► There is a well-formulated clinical question from 
which is possible to derive ‘necessary and sufficient 
testing’.
 ► The request arrives at the point of testing in a state 
that allows the question to be answered.
Clean through
 ► The consistency (or uncertainty) of the answer is 
described.
 ► The answer is available in time to answer the question.
Clean out
 ► Results are meaningful and helpful.
 ► Within the context of shared understanding of what 
matters to the life of the individual.
We developed a set of ‘test groups’ for primary care clini-
cians to use when ordering tests to monitor patients with a 
number of chronic diseases, particularly for QOF annual 
reviews. They were designed to ensure that only tests that 
were necessary and sufficient to provide an answer to the 
clinical question were included. We found it helpful to 
reframe problems as clinical questions as they would be 
seen from the perspective of the patient. For instance, 
the purpose of annual blood monitoring in patients with 
hypertension might be to ask, "Are my kidneys OK? Is 
there any evidence I am suffering side effects from my 
medication?" From this, we can see that the tests that 
would be necessary and sufficient to answer these ques-
tions would include only a renal profile (sodium, potas-
sium, creatinine and estimated glomerular filtration 
rate). This ‘outside-in’ approach provides a useful touch-
stone for interdisciplinary discussion about what consti-
tutes necessary and sufficient testing that often resolves 
conflict.
For chronic disease monitoring, what constitutes neces-
sary and sufficient testing to help answer the clinical 
question can be derived largely from NICE guidance. It is 
noteworthy how little of this guidance is based on robust 
evidence, and this often led to disagreement within the 
core project team about the role of some specific tests that 
were not recommended in some clinical contexts but that 
were traditionally requested. This was particularly true 
for FBCs and LFTs. It was notable that, although these 
were developed using best practice guidance, including 
NICE guidance where possible, the test groups tended to 
have fewer tests for chronic disease monitoring than the 
previous practice-derived groups, particularly with regard 
to FBC and LFT. We then set out to implement these test 
groups across the locality, and thereby reduce the varia-
tion of test protocols across the locality.
sTraTegy
Plan, do, study, act (Pdsa) cycle 1: developing monitoring 
measures and pilot study
To test acceptability of our test groups to a wider group of 
healthcare professionals, we initially introduced chronic 
disease test groups to the two practices of the GPs on the 
project team.
Lead GPs in each practice ensured that all staff were 
aware of the intervention. The laboratory IT team worked 
closely with healthcare assistants to ensure they could 
request the test groups using a single click in the primary 
care electronic ordering system. In both pilot practices, 
there was a rapid and significant fall in haemoglobin 
and bilirubin requesting rates (figure 1A and B). We 
concluded that test groups were an effective and accept-
able way of improving test ordering.
Pdsa cycle 2: using electronic ordering to rollout test 
groups at scale
Based on the findings of the pilot study, we released 
the test groups to all practices. We developed presenta-
tions to show the variation in current practice, the harm 
caused by current approaches to testing, the rationale for 
test groups and the effect of test groups on requesting 
volumes in pilot practices. We gave a talk to North Devon 
GPs in a half day educational forum.
We found that GPs were very supportive of the testing 
protocols and we had good feedback on the approach. 
However, over the next 3 months we saw only a slight 
drop in testing requests. To understand the barriers to 
implementation, we visited practices to discuss with GPs, 
nurses and healthcare assistants (HCAs). We found that 
in some practices (including pilot practice 2), the HCAs 
and nurses were using the protocols but adding back on 
the usual tests that they had been requesting for years. 
This can be seen, for instance, in the haemoglobin data 
from pilot practice 2 (figure 1A). They had thought that 
test groups had been introduced purely to save money. In 
other practices, even though clinicians were keen to use 
the protocols, the internal practice systems had not been 
changed. This requires time and commitment and they 
had other priorities.
We concluded that our laboratory data were a good 
way to monitor uptake and target interventions. In our 
experience, didactic events are rarely effective ways of 
delivering sustained change across a whole health system 
and it was important to design new forums for dialogue 
that involve the whole healthcare team. Furthermore, 
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implementation of new practice requires strong local 
clinical leadership and that this is likely to need signifi-
cant practical support.
Pdsa cycle 3: creating a pathology optimisation forum for 
peer-led improvement
Based on findings from the second cycle, we set up a 
pathology optimisation forum for practice HCA and GP 
leads to provide peer-led learning with input from labora-
tory staff. We managed to secure funding to release these 
people for a half day event every quarter.
At our first forum, we discussed practice uptake by 
showing data on haemoglobin and bilirubin test volumes 
by individual practice. This showed a drop in testing 
in 8 practices, but that 12 practices still did not appear 
to be using the protocols. There was discussion about 
barriers to implementation and we discovered a number 
of themes:
 ► Doing the right thing for patients and reducing work-
load are the key drivers for clinicians in primary care.
 ► A reluctance to let go of previous individual practice 
protocols.
 ► A worry that new diagnosis could be missed.
 ► Not appreciating the harm that can occur from 
de facto screening.
 ► Concerns about the rigour of the evidence review.
We were challenged to add a test (thyroid function) that 
was deemed missing from a testing protocol (new diag-
nosis of type 1 diabetes). We reviewed the updated NICE 
guidance on this topic, which suggests thyroid-stimulating 
hormone is measured at annual review in these patients. 
As a result, we changed the test group, improving on our 
initial work, increasing ownership outside of the project 
team and demonstrating how this approach facilitates 
keeping testing algorithms up to date.
We were challenged to remove annual cholesterol 
testing from cardiovascular protocols, which would be in 
line with NICE guidance. However, we chose to keep this 
in test groups as this was an area that many felt uncom-
fortable with, and we felt could be an additional barrier 
to change when there was still some reluctance to let go 
of FBC and LFT.
Pdsa cycle 4: responding to feedback with patient stories 
and test requesting data
At the next meeting of the pathology optimisation forum, 
we aimed to address the concerns raised at the initial 
meeting. We presented stories of how unnecessary testing 
leads to harm. The most potent example of this can be 
seen in the video of a patient with incidental detection of 
anaemia. We showed our data on how unnecessary testing 
creates additional workload. We showed that reductions 
in liver function testing had not significantly reduced the 
detection of pathologically raised ALT, suggesting that we 
were not missing disease.
Talking, listening and bringing back further infor-
mation to the forum levered the biggest change during 
implementation. In the following months, we saw the 
biggest drop in test requesting as a further 10 practices 
implemented the testing protocols. This left just two prac-
tices that were not consistently using test groups. These 
two remaining practices may need individual practice 
meetings to further discuss and understand local barriers.
measurement and analysis
We used laboratory requesting data for these tests to 
undertake an interrupted time series analysis to iden-
tify whether our interventions changed testing rates. 
We analysed the following, using the main rollout in 
September 2014 as the intervention date:
 ► Sodium as a marker for renal monitoring as these 
profiles were unaltered.
 ► Haemoglobin as a marker test for FBC.
 ► Bilirubin as a marker test for LFT.
 ► ALTs≥120 IU/L in order to measure rates of identi-
fication in possible significant pathology was altered 
by the intervention. This is the level at which statin 
therapy should be stopped.24
Figure 1 Monthly test requests for haemoglobin and 
bilirubin for chronic disease monitoring in pilot practice 1 (A) 
and 2 (B).
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resulTs
In 2012, blood tests that could be easily identified as 
part of chronic disease monitoring from clinical details 
accounted for 26% of renal profiles from primary care; 
18% of FBC requests from primary care and 26% of 
LFTs from primary care. The rolling annual average test 
volumes for chronic disease per 1000 registered patients 
in North Devon are shown in figure 2.
The effects of the interventions are clearly visible 
(figure 3).
Haemoglobin
Before the rollout haemoglobin test requests were stable 
(0.084; 95% CI −0.076 to 0.244). Following the rollout 
there was a clinically and statistically significant downward 
change in gradient (−0.350; 95% CI −0.546 to −0.154), 
with the rate of haemoglobin requests reducing from 
555 requests per 1000 patients in 2013 to 476 per 1000 
patients in 2016, a 14% decrease (figure 3A).
bilirubin
Before the rollout bilirubin test requests were stable 
(0.037; 95% CI −0.097 to 0.170). Following the rollout 
there was a clinically and statistically significant down-
ward change in gradient (−0.239; 95% CI −0.404 to 
−0.074), with the rate of bilirubin requests reducing from 
436 requests per 1000 patients in 2013 to 338 per 1000 
patients in 2016, a 22% decrease (figure 3B).
sodium
Before the rollout there there was a small rise in sodium 
requests (gradient: 0.221; 95% CI 0.054 to 0.387). 
Following the rollout there was no significant change in 
gradient (−0.142; 95% CI −0.364 to 0.080), with the rate 
of sodium tests increasing from 563 sodium tests per 1000 
patients in 2013 to 601 sodium tests per 1000 patients in 
2016; a 6.7% increase (figure 3C). This was in line with 
secular trends.
alT≥120 iu/l
Before the rollout there was a very slight downward 
change in ALT results ≥120 IU/L (gradient: 0.0027; 
95% CI −0.0052 to −0.0002). There was no significant 
reduction following the 2013 rollout (gradient: 0.0004; 
95% CI −0.0031 to 0.0040), with the rate being 3.4 per 
1000 patients in 2016 (figure 3D).
Figure 2 Estimated changes in common analyte requests for chronic diseases between April 2012 and March 2017 (rolling 
annual test volumes).
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Approximately 95% of primary care requests to our 
laboratory are now received electronically. Using labo-
ratory cost data, we can estimate that our intervention 
has reduced marginal (or reagent only) costs by approxi-
mately £18 000 per year. However, using NICE reference 
costs,25 this is nearer to £200 000 reduction in actual 
annual testing costs.
lessons learnt
We have shown that it is possible to create a framework 
for quality improvement in diagnostic medicine that is 
focused on what matters to patients, and can be used 
to deliver large and important improvements in service 
delivery. At the beginning of the project we saw that, in 
the absence of clear clinical reasons to test, there is the 
potential to cause harm which adversely affects patients 
and increases costs and workload across the healthcare 
system. There is also the risk that the signal of signifi-
cant pathology becomes lost in the noise of incidental, 
clinically irrelevant findings. We have found that clini-
cians learn to ignore mildly abnormal results, as most 
are inconsequential and derived from testing that is not 
necessary. However, this learning process occurs at vari-
able rates and will be highly clinician dependent, leading 
to an inconsistency in approach.
The framework helped identify the issues that exist across 
service boundaries, and led to a increase in collaboration 
across the system. Creating a discussion forum facilitated 
peer-to-peer interactions, allowed sharing of success and 
provided support and challenge to any proposed changes. 
Patient stories can be powerful, but we believe the validity 
of these are enhanced through use of additional informa-
tion to reassure people that changes are safe. Measuring 
potential harms of ‘missed diagnoses’ through reduced 
testing is challenging. However, we saw no significant reduc-
tion in either sodium levels (where profiles had not be 
altered) or the number of ALT results that are commonly 
believed to need further investigation (three times upper 
limit of normal). This suggests that the framework does not 
increase the risk of a missed diagnosis.
We are starting to use our framework to develop more 
rational approaches to the use of tests for diagnosis of 
illness. This is a significant challenge: evidence and guid-
ance is usually even more sparse while practice is often 
highly variable, as are the wishes and needs of patients. 
We will need to embrace methods of shared decision 
making that facilitate true partnership working between 
clinician and patient, recognising that ‘one-size-fits-all' 
approaches are likely to lead to disenfranchisement.26 
We are also exploring how other aspects of the Clean 
Framework can be used to improve care, and have begun 
to see improvements in a number of areas, including 
specimen stabilisation, measurement of uncertainty, defi-
nitions of timeliness and reporting of results to patients. 
However, in all cases we have found that a focus on 
‘clean in’ is a key initial step of any improvement work, 
as well as sustaining change. We have continued with the 
pathology optimisation forum and have continued to 
co-create guidelines and review test groups where neces-
sary, as well as to discuss other barriers to improvement. 
We believe that this continued engagement has led to 
Figure 3 Interrupted time series analysis. (A) Haemoglobin tests per 1000 patients, (B) bilirubin tests per 1000 patients, (C) 
sodium tests per 1000 patients, (D) alanine aminotransferase (ALT)≥120 IU/L results per 1000 patients.
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sustained improvement, although we are yet to quantify 
the benefits.
limiTaTions
One limitation was the lack of robust evidence on which 
to base our chronic disease test groups. Although we used 
NICE guidelines to ensure chronic disease test groups 
were in line with current recommendations, we do not 
formally know these are necessary and sufficient to answer 
the clinical question. Therefore, although this seemed 
the best starting point, areas of uncertainty persisted. For 
example, annual cholesterol testing for cardiovascular 
profiles was included, which was not strictly required 
based on NICE guidelines, but that felt important to get 
local clinical ‘buy-in’. We believe more research is needed 
in this area. In addition, our demonstrable continuous 
review of the basis for our test groups was an important 
part of gaining clinical acceptance and provides a level 
of governance that individual practices would find hard 
to sustain.
Although we interviewed patients in order to iden-
tify problems, due to team resource we were not able to 
undertake a patient satisfaction survey. We will consider 
undertaking this as part of future improvement cycles.
conclusion
A systematic approach that aligns the use of common 
blood tests to valid clinical questions has produced signif-
icant reductions in cost, workload and harm, without a 
corresponding reduction in the identification of signifi-
cant pathology. This has led to an overall improvement in 
service quality. Our methodology is now embedded into 
the culture and governance processes of both the local 
laboratory and primary care, ensuring sustainability.
We suspect that chronic disease ordering elsewhere will, 
in the main, include FBC and LFT. If this is the case, then 
they should be able to replicate these results. However, 
we would be wary of suggesting that these gains could 
be delivered by simple implementation of test groups 
in electronic ordering. This was just part of a wide and 
deep engagement process. In summary, we believe the 
following actions were key to success of our work:
 ► Creating a forum for dialogue and co-production 
involving all stakeholders.
 ► Using what matters to people, including patient 
stories, as the foundation for engagement.
 ► Using data to discover problems, while recognising 
the limitations inherent in analyses.
 ► Creating tight feedback loops with an open learning 
culture.
 ► Understanding the needs of stakeholders.
 ► Making it easy to do the right thing.
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